Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Neurology | Oncology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Quadramet (Samarium Sm 153 Lexidronam Injection)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: DuPont Merck Pharmaceutical Company
Approval Status: Approved March 1997
Treatment Area: pain associated with bone cancer
Quadramet (Samarium Sm 153 Lexidronam Injection) has been
approved to treat the severe pain associated with cancers that have
spread to bone. It is indicated for relief of pain in patients with
confirmed osteoblastic metastatic bone lesions that enhance on
radionuclide bone scan.
This condition is most often experienced by patients with
prostate, breast or lung cancers that have spread to the bone.
Quadramet is a radiopharmaceutical that may be administered as a
single intravenous injection on an outpatient basis.
Mechanism of Action
Clinical studies show that Quadramet targets the sites of new
bone formation, concentrating in regions of the bone that have been
invaded with metastatic tumor. The drug goes to the source of
cancer bone pain and irradiates the osteoblastic tumor sites
resulting in relief of pain. The onset of pain relief was
experienced as early as one week in the majority of patients.
Estimates, including those from the American Cancer Society and
National Cancer Institute, show that over 200,000 patients annually
in the United States will experience severe, chronic pain
associated with bone metastases.